Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irofulven + Prednisolone in DRP-Selected mCRPC
NCT03643107Phase 2Completed
- Sponsor
- Allarity Therapeutics
- Start
- Oct 2018
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irofulven in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Allarity Therapeutics. Primary endpoint: Anti-tumor effect of Irofulven with prednisolone at 1 year. Started Oct 2018; status: completed.
02
Drugs
irofulven
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03643107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03643107.